Raywatt, a cardiovascular medical device startup, secured 8.5 billion KRW in Series A funding, enhancing its prospects for innovation and market expansion.

Target Information

Raywatt, a startup specializing in interventional cardiovascular medical devices, has successfully secured a Series A investment totaling 8.5 billion KRW, bringing its cumulative funding to over 10 billion KRW. The company is recognized for its innovative technology, particularly its OCT-based cardiovascular diagnostic capabilities combined with artificial intelligence solutions.

The flagship product, FASTER, utilizes an advanced OCT imaging system that scans the interiors of coronary arteries at an impressive speed of 400 frames per second. This technology provides real-time high-resolution 2D and 3D imaging while minimizing patient discomfort and the risk of adverse effects. Unlike traditional OCT devices that require contrast agents, Raywatt's system employs saline solution, enhancing patient safety during diagnostics.

Industry Overview in South Korea

The healthcare industry in South Korea has been experiencing significant growth, particularly in the medical device sector. With a strong emphasis on innovation and research, South Korea has become a hub for advan